Global CRO INC Research Holdings has announced a strategic collaboration with DrugDev to drive increased efficiencies in clinical trials through enhanced access to and management of critical investigator and site data. INC Research becomes the first CRO to complete integration with and implementation of DrugDev’s SiteCloud platform, the same technology used by TransCelerate’s Investigator Registry (launching later this year) and the Investigator Databank, to facilitate more efficient feasibility, site selection and study start-up processes.

DrugDev is an innovative technology company that provides unified global solutions to help sponsors, CROs and sites do more trials together. Using a universal identifier known as the DrugDev Golden Number, the SiteCloud platform matches and masters data from numerous disparate sources (such as INC’s internal experience, the DrugDev Network of 80,000 opted-in global investigators across 115 countries and trusted third-party resources) to create a virtual private database (VPD) for INC with precise site and investigator profiles that will be used to make superior evidence-based decisions.

SiteCloud enables INC Research to make evidence-driven site selection decisions, while the DrugDev Golden Number enables INC to collaborate and integrate more efficiently with pharmaceutical customers also using the DrugDev platform. The adoption of this technology further demonstrates INC’s commitment to finding the right sites for every clinical trial, which in turn improves the clinical research process for global sites and sponsors alike.

INC will continue to work with DrugDev on implementation of additional innovative technologies that improve clinical development and bring new medicines to patients faster.

“Real change will only come to the clinical research industry through meaningful collaboration and the widespread adoption of technology standards such as the DrugDev Golden Number, so naturally we could not be more excited to work with INC Research on this essential initiative,” said Ibraheem (Ibs) Mahmood, president and CEO of DrugDev. “As a platform-agnostic leader, INC is committed to leveraging future-proof technologies that best meet customer requirements, and we are honored that they have chosen SiteCloud as their preferred platform for site and investigator data sharing and management.”